小儿消积止咳口服液联合丙卡特罗治疗小儿咳嗽变异性哮喘的临床研究  

Clinical study on Xiaoer Xiaoji Zhike Oral Liquid combined with procaterol in treatment of cough variant asthma in children

作　　者：刘冬岩 孙方舟 姚国华[2] LIU Dong-yan;Sun Fang-zhou;YAO Guo-hua(Department of Pediatrics, Sino-singapore Eco-city Hospital of Tianjin Medical University,Tianjin 300467,China;Department of Respiratory, Tianjin Children's Hospital, Tianjin 300000,China)

机构地区：[1]天津医科大学中新生态城医院儿科,天津300467 [2]天津市儿童医院呼吸二科,天津300000

出　　处：《现代药物与临床》2019年第7期2064-2068,共5页Drugs & Clinic

摘　　要：目的探讨小儿消积止咳口服液联合丙卡特罗治疗小儿咳嗽变异性哮喘的临床疗效。方法 2018年3月-2019年3月在天津医科大学中新生态城医院进行治疗的86例咳嗽变异性哮喘患儿,根据用药的差别分为治疗组(43例)和对照组(43例)。对照组口服盐酸丙卡特罗口服溶液,1~3岁,2 mL/次,4~6岁,2.5 mL/次,2次/d。治疗组在对照组基础上口服小儿消积止咳口服液,1~2岁,10 mL/次,3~4岁,15 mL/次;5岁以上,20 mL/次;3次/d。两组均治疗2周。观察两组的临床疗效,比较两组治疗前后LCQ评分、C-ACT评分、MARS-A评分、一秒用力呼气容积(FEV1)、最大呼气流量(PEF)、血清学指标的变化情况。结果治疗后,对照组和治疗组的总有效率分别是81.40%、97.67%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组LCQ评分、C-ACT评分、MARS-A评分、FEV1、PEF均较治疗前显著增高,同组治疗前后比较差异有统计学意义(P<0.05);治疗后,治疗组LCQ评分、C-ACT评分、MARS-A评分、FEV1、PEF显著高于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组血清人组织金属蛋白酶抑制因子-1(TIMP-1)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、人半胱氨酰白三烯(CysLTs)水平均较治疗前显著下降,而白细胞介素-2(IL-2)、干扰素-γ(IFN-γ)水平均显著增高,同组治疗前后比较差异有统计学意义(P<0.05);治疗后,治疗组TIMP-1、IL-6、TNF-α、CysLTs水平低于对照组,而IL-2、IFN-γ高于对照组,两组比较差异具有统计学意义(P<0.05)。结论小儿消积止咳口服液联合丙卡特罗治疗小儿咳嗽变异性哮喘具有较好的临床疗效,可有效改善患儿的临床症状,改善患儿肺功能和生活质量,改善机体细胞因子水平,具有一定的临床推广应用价值。Objective To explore the clinical effect of Xiaoer Xiaoji Zhike Oral Liquid combined with procaterol in treatment of cough variant asthma in children. Methods 86 Children with cough variant asthma in Sino-singapore Eco-city Hospital of Tianjin Medical University from March 2018 to March 2019 were divided into control group(43 cases) and treatment group(43 cases) according to the difference of medication. Patients in the control group were po administered with Procaterol Hydrochloride Oral Solution, 1 - 3 years old, 2 mL/time, 4 - 6 years old, 2.5 mL/time, twice daily. Patients in the treatment group were po administered with Xiaoer Xiaoji Zhike Oral Liquid on the basis of control group, 1 - 2 years old, 10 mL/time;3 - 4 years old, 15 mL/time;over 5 years old, 20 mL/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated,and the changes of LCQ score, C-ACT score, MARS-A score, FEV1, PEF, and serological indicators in two groups were compared.Results After treatment, the clinical efficacy in the control and treatment groups were 81.40% and 97.67%, respectively, and there were differences between two groups(P < 0.05). After treatment, LCQ score, C-ACT score, MARS-A score, FEV1, and PEF in two groups were significantly increased, and there were differences in the same group(P < 0.05). After treatment, LCQ score, C-ACT score, MARS-A score, FEV1, and PEF in the treatment group were significantly higher than those in the control group, and there were differences between two groups(P < 0.05). After treatment, TIMP-1, IL-6, TNF-α, and CysLTs in two groups were significantly decreased, but IL-2 and IFN-γ were significantly increased, and there were differences in the same group(P < 0.05). After treatment,TIMP-1, IL-6, TNF-α, and CysLTs in the treatment group were lowerer than those in the control group, but IL-2 and IFN-γ were higher than those in the control group, and there were differences between two groups(P < 0.05). Conclusion Xiaoer Xiaoji Zh

关 键 词：小儿消积止咳口服液 盐酸丙卡特罗口服溶液 咳嗽变异性哮喘 LCQ评分 C-ACT评分 MARS-A评分 一秒用力呼气容积 最大呼气流量 人组织金属蛋白酶抑制因子-1 白细胞介素-6 肿瘤坏死因子-α 人半胱氨酰白三烯 

分 类 号：R974[医药卫生—药品]